Trinity Biotech(TRIB) - 2025 Q3 - Earnings Call Presentation

Financial Results (Unaudited) For Quarter Ended September 30, 2025 Overview Q3 2025 Financial Results - Summary • Revenue for the quarter ended as of 30 September 2025 on a like-for-like basis (excluding sub-scale lower- margin third-party product lines) was $14.2m vs Q3, 2024 $14.6m. • The Company experienced significant quarter-on-quarter increase in revenue in Q3, 2025 following strong UniGold HIV sales combined with the resumption in manufacture and supply of its flagship rapid HIV test, TrinScreen HIV ...